What is ST9.5? Comparison Applications FAQ 日本語 Contact Us

ST9.5: Expanding Genome Editing
Beyond Conventional Platforms

A New Option Designed to Address Cost and IP Challenges in Genome Editing

Reduced Licensing
Costs

Minimize licensing expenses and develop a commercialization strategy tailored to your application.

Reduced IP
Complexity

Support development planning with a clearer understanding of relevant IP considerations.

Long-Term IP
Position

Patent protection is currently projected through 2044, supporting long-term research and commercialization planning.

Cross-Species
Applicability

Applicable across a wide range of species, including livestock, aquaculture species, plants, and microorganisms.

Discuss ST9.5 for Your Project

Facing Challenges with
Existing Genome Editing Tools?

Commercial licensing costs are limiting adoption.

Managing licenses from multiple IP holders is complex and time-consuming.

Selecting the right editing platform for different species requires significant evaluation effort.

Address Your Genome Editing Challenges with ST9.5

ST9.5 is an RNA-guided nuclease that operates through a mechanism distinct from conventional Cas9-based systems.
It enables genome editing strategies independent of existing Cas9-based tools.

Category ST9.5 Conventional Genome Editing Platforms
Primary Licensing Entity
Setsuro Tech
Multiple Organizations
Licensing Burden
Lower (Flexible Licensing Options)
Often Significant
Applicability
Cells, Microorganisms, Livestock, and More
Application-Dependent
Discuss ST9.5 for Your Project

What is ST9.5?

ST9.5 is a proprietary RNA-guided nuclease developed and patented by
Setsuro Tech, a biotechnology company originating from Tokushima University.
(Japanese Patent No. 7662138)

RNA-Guided
Nuclease

Targeted DNA
Cleavage

Designed for Broad
Species Applicability

Ideal Applications

Microbial Strain Improvement
Cell Line Development
Evaluation of Alternative Genome Editing Platforms
Livestock Breeding & Trait Improvement

Research Applications

Poultry Breeding

In-Ovo Sex Determination

Swine Breeding

Disease Resistance in Swine
Contact Us

Areas of Expertise

Animal Breeding

Supporting genetic improvement across diverse animal species.

Microbial Engineering

Enhancing productivity and enabling the production of valuable compounds through microbial engineering.

Mammalian Cell Engineering

Supporting functional modification and optimization of mammalian cell lines.

Genome Engineering
(Knock-in / Knockout)

Supporting a broad range of genome engineering applications, including targeted gene insertion and disruption.

Emerging Application Areas

Exploring future applications across advanced therapeutic and biotechnology fields.

  • Viral Vector Engineering (Lentiviral / Retroviral)
  • Cell Therapy (Including CAR-T Genome Engineering)
  • RNA Delivery (Potential Integration with LNP and RNP-Based In Vivo Editing Approaches)
  • Production Cell Line Engineering (Including HEK293 Optimization)
  • Organoid Engineering

*Some applications are currently under evaluation in research and development settings. Please contact us for details.

CAR-T

Implementation Process

STEP 1
Initial Consultation
STEP 2
Technical Assessment
STEP 3
Feasibility Evaluation
STEP 4
Pilot Collaboration & Implementation

We provide application-specific guidance throughout evaluation, implementation,
and ongoing utilization based on your project goals and target species.

Frequently Asked Questions

Do you hold patent rights for ST9.5?
Yes. ST9.5 is a proprietary RNA-guided nuclease developed by Setsuro Tech and protected under Japanese Patent No. 7662138. Additional information regarding scope of use and licensing can be discussed on a case-by-case basis.
How do you address IP and freedom-to-operate considerations?
We continuously conduct Freedom-to-Operate (FTO) assessments to evaluate and manage potential intellectual property risks. Project-specific discussions regarding territories, applications, and commercialization pathways are also available.
Is a trial evaluation available?
Yes. We support technical evaluation and feasibility studies during the research and development phase. Following execution of an MTA (Material Transfer Agreement), partners can assess ST9.5 before considering broader implementation.
Has sufficient nuclease activity been demonstrated?
Target-specific cleavage activity has been confirmed through internal validation studies. Because performance may vary depending on target and experimental conditions, detailed data can be shared following execution of an NDA.

Whether you are actively evaluating genome editing platforms or simply exploring future options, we welcome the opportunity to discuss your needs.

• Evaluation of genome editing approaches independent of conventional platforms
• Species-specific feasibility assessments
• Genome editing strategies for future commercial applications
• Technical consultation for new business initiatives and collaborative research

Discuss ST9.5 for Your Project